The Company Overview Contacts Riku Rautsola, PhD President and Chief Executive Officer [email protected] Gerard Fleury, EVP and CFO [email protected] Gary McGarrity, PhD EVP Scientific and Clinical Affairs [email protected] Address VIRxSYS Corporation 200 Perry Parkway, Suite 1A Gaithersburg, MD 20877 United States Telephone 301-987-0480 Fax 301-987-0489 Year Founded 1998 Financial Summary Fundraising and Strategic Outlook The […]
Read More..VIRxSYS has taken proof-of-concept studies performed at The Johns Hopkins University, completed its Phase I clinical trials in humans, and has initiated Phase II clinical trials in less than seven years. Company milestones are as follows: Date Milestone 1998 VIRxSYS incorporated 1999 First round of fundraising completed 2000 Initial meeting with the FDA to discuss the […]
Read More..VIRxSYS has developed a proprietary HIV-based lentiviral vector gene delivery system, from which the disease-causing aspects of the virus have been removed, leaving behind an efficient delivery vehicle. In order to provide a therapy against HIV, VIRxSYS has equipped the vector with a long antisense sequence against the HIV envelope protein to create VRX496. The […]
Read More..VIRxSYS has raised over $80 million through six rounds of financing thanks to the support of our investors. Without their continued support and enthusiasm, the Company would not be able to develop technology that delivers on the promise of genetic medicine, allowing for the treatment of serious human diseases. Technology Advancement VIRxSYS intends to develop […]
Read More..Getting to the Root Cause of Disease Gene therapy is the treatment of hereditary or infectious diseases by repairing or re-engineering the genome. The therapy’s goal is to treat the genetic cause of disease rather than merely treating the symptoms. The advantage of gene therapy over traditional treatments is the elimination or reduction of the […]
Read More..Medical Advisory Board VIRxSYS has assembled a Medical Advisory Board comprised of experts in HIV medicine. The Medical Advisory Board offers guidance in the design and execution of the Company’s HIV clinical trials, and guidance in positioning VRX496. The members of the Medical Advisory Board include: Member Affiliation Brigitte Autran, MD, PhD Groupe Hospitalier Pitie-Salpetriere […]
Read More..VIRxSYS has developed an extensive portfolio of intellectual property which is protected by a combination of patents, trade secrets, and trademark law. Below is a summary of the Company’s parent patents in the United States. VIRxSYS also has many foreign counterparts in countries around the world. Patent/Ser No. Issue / Publication Date Title US 5,885,806 […]
Read More..VIRxSYS is the only company currently testing a lentiviral vector permitted for use by the FDA in Phase II clinical trials. Consequently, VIRxSYS is uniquely positioned to manufacture clinical-grade lentiviral vectors for therapies treating a wide range of life-threatening diseases. VIRxSYS is initially focused on using lentiviral vectors in cellular therapies for HIV/AIDS. VIRxSYS both […]
Read More..